NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Dr. Liau herself has encouraged idh mutant tumor patients to pursue other options, and Dr. Prins and Dr. Liau have long thought Proneural (aka idh mutant) is likely less responsive to DCVax-l. Also, it seems a bit cavalier to suggest the reclassification of GBM now excluding idh (and H3) mutant will not have impact on DCVax-l’s trial interpretations and every other GBM trial for that matter. It’s a big deal.

GBM, as it is now internationally defined, will be more responsive to DCVax-l than GBM as it was previously defined.

It’s that simple. IMO.